MEK-ERK inhibition potentiates WAY-600-induced anti-cancer efficiency in preclinical hepatocellular carcinoma (HCC) models.

scientific article published on 21 April 2016

MEK-ERK inhibition potentiates WAY-600-induced anti-cancer efficiency in preclinical hepatocellular carcinoma (HCC) models. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/J.BBRC.2016.04.099
P698PubMed publication ID27107695

P2093author name stringPeng Zhang
Dexin Kong
Zhengrong Wang
Kaifeng Wang
Gongying Chen
Yaohua Fan
P433issue2
P407language of work or nameEnglishQ1860
P921main subjecthepatocellular carcinomaQ1148337
P304page(s)330-337
P577publication date2016-04-21
P1433published inBiochemical and Biophysical Research CommunicationsQ864228
P1476titleMEK-ERK inhibition potentiates WAY-600-induced anti-cancer efficiency in preclinical hepatocellular carcinoma (HCC) models.
P478volume474

Reverse relations

cites work (P2860)
Q47103348ERK inhibition sensitizes CZ415-induced anti-osteosarcoma activity in vitro and in vivo
Q55440708FABP4 suppresses proliferation and invasion of hepatocellular carcinoma cells and predicts a poor prognosis for hepatocellular carcinoma.
Q92382925FIBCD1 overexpression predicts poor prognosis in patients with hepatocellular carcinoma
Q47156516Jujube leaf green tea extracts inhibits hepatocellular carcinoma cells by activating AMPK.
Q37664313Lymphocyte-specific protein 1 inhibits the growth of hepatocellular carcinoma by suppressing ERK1/2 phosphorylation
Q41549602Tumor-specific hepatic stellate cells (tHSCs) induces DIgR2 expression in dendritic cells to inhibit T cells

Search more.